The use of biochemical markers in osteoporosis

Clinics in Laboratory Medicine

Volumn 24, Issue 1, 2004, Pages 175-197

  Hammett Stabler, Catherine A ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALCOHOL; ALKALINE PHOSPHATASE BONE ISOENZYME; ALUMINUM; AMINO TERMINAL TELOPEPTIDE; ANASTROZOLE; ANTACID AGENT; ANTICONVULSIVE AGENT; AROMATASE INHIBITOR; BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; COLESTYRAMINE; COLLAGEN; CYCLOSPORIN; DEOXYPYRIDINOLINE; DIURETIC AGENT; GLUCOCORTICOID; GONADORELIN ANTAGONIST; HEPARIN; LEUPRORELIN; LITHIUM; METHOTREXATE; NEUROLEPTIC AGENT; OSTEOCALCIN; PHOSPHATE BINDING AGENT; PYRIDINOLINE; SIALOPROTEIN; TACROLIMUS; THYROXINE;

BONE DENSITY; BONE DISEASE; BONE MASS; BONE MINERAL; BONE TURNOVER; CALCIUM URINE LEVEL; CELL ACTIVITY; CROSS LINKING; DIAGNOSTIC PROCEDURE; DUAL ENERGY X RAY ABSORPTIOMETRY; HUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW;

BIOLOGICAL MARKERS; BONE RESORPTION; HUMANS; OSTEOPOROSIS;

EID: 2442515292     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cll.2004.01.013     Document Type: Review

References (81)

1. Brown MA, Haughton MA, Grant SF, Gunnell AS, Henderson NK, Eisman JA. Genetic control of bone density and turnover: role of the collagen 1alpha1, estrogen receptor and vitamin D receptor genes. J Bone Miner Res 2001;16:758-64.
2. Harris M, Nguyen TV, Goward GM, Kelly PJ, Eisman JA. Genetic and environmental correlations between bone formation and bone mineral density: a twin study. Bone 1998;22:141-5.
3. Liu YZ, Liu YJ, Recker RR, Deng HW. Molecular studies of identification of genes for osteoporosis: the 2002 update. J Endocrinol 2003;177:147-96.
4. Mann V, Hobson EE, Baobua L, Stewart TL, Grant SF, Robins SP, et al. A COL1A1 Sp1 binding site polymorphism predisposes to osteoporotic fracture by affecting bone density and quality. J Clin Invest 2001;107:899-907.
5. Licata A. Osteoporosis in men: suspect secondary disease first. Cleve Clin J Med 2003;70:247-54.
6. Canalis E, Delany AM. Mechanisms of glucocorticoid action in bone. Ann N Y Acad Sci 2002;966:73-81.
7. Melton LJ, Achenbach SJ, O'Fallon WM, Khosla S. Secondary osteoporosis and the risk of distal forearm fractures in men and women. Bone 2002;31:119-25.
8. Fitzpatrick LA. Secondary causes of osteoporosis. Mayo Clin Proc 2002;77:453-68.
9. Ethane O, Teller V, Seiren WB, De Meaner J, Gusset C, Register JY. Health-related quality of life and cost of ambulatory care in osteoporosis: how may such outcome measures be valuable information to health decision-makers and payers? Bone 2003;32:718-24.
10. Newman ED, Ayoub WT, Starkey RH, Diehl JM, Wood GC. Osteoporosis disease management in a rural health care population: hip fracture reduction and reduced costs in postmenopausal women after 5 years. Osteoporos Int 2003;14:146-51.
11. Khan A. Advances in osteoporosis therapy: 2003 update of practical guidelines. Can Fam Physician 2003;49:441-7.
12. America's bone health: the state of osteoporosis and low bone mass in our nation. Washington, DC: National Osteoporosis Foundation; 2002.
13. Farrell E. Medical choices available for management of menopause. Best Pract Res Clin Endocrinol Metab 2003;17:1-16.
14. Follin SL, Hansen LB. Current approaches to the prevention and treatment of postmenopausal osteoporosis. Am J Health Syst Pharm 2003;60:883-901.
15. Woitge HW, Scheidt-Nave C, Kissling C, Leidig-Bruckner G, Meyer K, Grauer A, et al. Seasonal variation of biochemical indexes of bone turnover: results of a population-based study. J Clin Endocrinol Metab 1998;83:68-75.
16. Hoshino H, Kushida K, Takahashi M, Kawana K, Denda M, Yamazaki K, et al. Characteristics of biochemical markers in patients with metabolic bone disorders. Endocr Res 1998;24:55-64.
17. Glerup H, Mikkelsen K, Poulsen L, Hass E, Overbeck S, Thomsen J, et al. Commonly recommended daily intake of vitamin D is not sufficient if sunlight exposure is limited. J Intern Med 2000;247:260-8.
18. Sahota O, Hosking DJ. The contribution of nutritional factors to osteopenia in the elderly. Curr Opin Clin Nutr Metab Care 2001;4:15-20.
19. Bischoff H, Stahelin HB, Vogt P, Friderich P, Vonthein R, Tyndall A, et al. Immobility as a major cause of bone remodeling in residents of a long-stay geriatric ward. Calcif Tissue Int 1999;64:485-9.
20. Mora S, Pitukeheewanont P, Kaufman FR, Nelson JC, Gilsanz V. Biochemical markers of bone turnover and the volume and the density of bone in children at different stages of sexual development. J Bone Miner Res 1999;14:1664-71.
21. Mora S, Prinster C, Proverbio MC, Belini A, de Poli SCL, Weber G, et al. Urinary markers of bone turnover in health children and adolescents: age-related changes and effect of puberty. Calcif Tissue Int 1998;63:369-74.
22. Szule P, Seeman E, Delmas PD. Biochemical measurements of bone turnover in children and adolescents. Osteoporos Int 2002;11:281-94.
23. Van Coeverden SCCM, Netelenbos JC, de Ridder CM, Roos JC, Popp-Snijders C, Delemarre-vande Waal HA. Bone metabolism markers and bone mass in healthy pubertal boys and girls. Clin Endocrinol (Oxf) 2002;57:107-16.
24. Ebeling PR, Atley LM, Guthrie JR, Burger HG, Dennerstein L, Hopper JL, et al. Bone turnover markers and bone density across the menopausal transition. J Clin Endocrinol Metab 1996;81:3366-71.
25. Fall PM, Kennedy D, Smith JA, Seibel MJ, Raisz LG. Comparison of serum and urine assays for biochemical markers of bone resorption in postmenopausal women with and without hormone replacement therapy and in men. Osteoporos Int 2000;11:481-5.
26. Fink E, Cormier C, Steinmetz P, Kindermans C, Le Bouc Y, Souberbielle JC. Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy. Osteoporos Int 2002;1:295-303.
27. Kushida K, Takahashi M, Kawana K, Inoue T. Comparison of markers for bone formation and resorption in premenopausal and postmenopausal subjects and osteoporosis patients. J Clin Endocrinol Metab 1995;80:2447-50.
28. Riggs BL, O'Fallon WM, Muhs J, O'Connor MK, Kumar R, Melton LJ III. Long-term effects of calcium supplementation on serum parathyroid hormone level, bone turnover, and bone loss in elderly women. J Bone Miner Res 1998;13:168-74.
29. Roger A, Saleh G, Hannon RA, Greenfield D, Eastell R. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. J Clin Endocrinol Metab 2002;87:4470-5.
30. Aloia JF, Mikhail M, Pagan CD, Arunacha-Lam A, Yeh JK, Flaster E. Biochemical and hormonal variables in black and white women matched for age and weight. J Lab Clin Med 1998;132:383-9.
31. Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C. Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps): follow-up on hormone replacement therapy and osteoporosis risk assessment. J Clin Endocrinol Metab 1995;80:864-8.
32. Finkelstein JS, Sowers M, Greendale GA, Lee MT, Neer RM, Cauley JA, et al. Ethnic variation in bone turnover in pre-and early perimenopausal women: effects of anthropometric and lifestyle factors. J Clin Endocrinol Metab 2002;87:3051-6.
33. Gallagher JC, Kinyamu HK, Fowler SE, Dawson-Hughes B, Dalsky GP, Sherman SS. Calciotropic hormones and bone markers in the elderly. J Bone Miner Res 1998;13:475-82.
34. Minisola S, Dionisi S, Pacitti T, Paglia F, Carnevale V, Scillitani A, et al. Gender differences in serum markers of bone resorption in healthy subjects and patients with disorders affecting bone. Osteoporos Int 2002;13:171-5.
35. Krall EA, Dawson-Hughes B, Hirst K, Gallagher JC, Sherman SS, Dalsky G. Bone mineral density and biochemical markers of bone turnover in healthy elderly men and women. J Gerontol A Biol Sci 1997;52A:M61-7.
36. Wishart JM, Need AG, Horowitz M, Morris HA, Nordin BEC. Effect of age on bone density and bone turnover in men. Clin Endocrinol 1995;42:141-6.
37. Popp-Snijders C, Lips P, Netelenbos JC. Intra-individual variation in bone resorption markers in urine. Ann Clin Biochem 1996;33:347-8.
38. Halleen JM, Ylipahkala H, Alatalo SL, Janckila AJ, Heikkinen JE, Suominen H, et al. Serum tartrate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density. Calcif Tissue Int 2002;71:20-5.
39. Alatalo SL, Halleen JM, Hentunen TA, Monkkonen J, Vaananen HK. Rapid screening method for osteoclast differentiation in vitro that measures tartrate-resistant acid phosphatase 5b activity secreted into the culture medium. Clin Chem 2000;46:1751-4.
40. Raynal C, Delmas PD, Chenu C. Bone sialoprotein stimulates in vitro bone resorption. Endocrinology 1996;137:2347-54.
41. Harris NL, Rattray KR, Tye CE, Underhill TM, Somerman MJ, D'Errico JA, et al. Functional analysis of bone sialoprotein: identification of the hydroxyapatite-nucleating and cell-binding domains by recombinant peptide expression and site-directed mutagenesis. Bone 2000;27:795-802.
42. Fontana A, Delmas PD. Markers of bone turnover in bone metastases. Cancer 2000;88:2952-60.
43. Withold W, Armbruster FP, Karmatschek M, Reinauer H. Bone sialoprotein in serum of patients with malignant bone diseases. Clin Chem 1997;43:85-91.
44. Fledelius C, Johnsen AH, Cloos PAC, Bonde M, Qvist P. Characterization of urinary degradation products derived from type I collagen. J Biol Chem 1997;272:9755-63.
45. Meddah B, Kamel S, Giroud C, Brazier M. Effects of ultraviolet light on free and peptide-bound pyridinoline and deoxypyridinoline cross-links: protective effect of acid pH against photolytic degradation. J Photochem Photobiol B 2000;54:168-74.
46. Sarno M, Powell H, Tjersland G, Schoendorfer D, Harris H, Adams K, et al. A collection method and high-sensitivity enzyme immunoassay for sweat pyridinoline and deoxypyridinoline cross-links. Clin Chem 1999;45:1501-9.
47. Cloos PAC, Fledelius C. Collagen fragments in urine derived from bone resorption are highly racemized and isomerized: a biological clock of protein aging with clinical potential. Biochem J 2000;345:473-89.
48. Osteomark NTx Point-of-Care Product Description. Available at: http://www.osteomark.com/Products/Point_Of_Care_Description.asp. Accessed May 2003.
49. Jakob C, Zavrski I, Heider U, Brux B, Eucker J, Langelotz C, et al. Bone resorption parameters [carboxy-terminal telopeptide of type-I collagen (ICTP), amino-terminal collagen type-I telopeptide (NTx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma. Eur J Haematol 2002;69:37-42.
50. Hessle L, Johnson KA, Anderson HC, Narisawa S, Sali A, Goding JW, et al. Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization. Proc Natl Acad Sci USA 2002;99:9445-9.
51. Heinemann DE, Siggelkow H, Ponce LM, Viereck V, Wiese KG, Peters JH. Alkaline phosphatase expression during monocyte differentiation: overlapping markers as a link between monocytic cells, dendritic cells, osteoclasts and osteoblasts. Immunobiology 2000;202:68-81.
52. Zittermann A. Effects of vitamin K on calcium and bone metabolism. Curr Opin Clin Nutr Metab Care 2001;4:483-7.
53. Sugiyama T, Kawai S. Carboxylation of osteocalcin may be related to bone quality: a possible mechanism of bone fracture prevention by vitamin K. J Bone Miner Metab 2001;19:146-9.
54. Feskanich D, Weber P, Willett WC, Rockett H, Booth SL, Colditz GA. Vitamin K intake and hip fractures in women: a prospective study. Am J Clin Nutr 1999;69:74-9.
55. Tracy RP, Andrianorivo A, Riggs BL, Mann KG. Comparison of monoclonal and polyclonal antibody-based immunoassays for osteocalcin: a study of sources of variation in assay results. J Bone Miner Res 1990;5:451-61.
56. Masters PW, Jones RG, Purves DA, Cooper EH, Cooney JM. Commercial assays for serum osteocalcin give clinically discordant results. Clin Chem 1994;40:358-63.
57. Vesper HW, Demers LM, Eastell R, Garnero P, Kleerekoper M, Robins SP, et al. Assessment and recommendations of factors contributing to preanalytical variability of urinary pyridinoline and deoxypyridinoline. Clin Chem 2002;48:220-35.
58. Rapuri PB, Kinyamu HK, Gallagher JC, Haynatzka V. Seasonal changes in calciotropic hormones, bone markers, and bone mineral density in elderly women. J Clin Endocrinol Metab 2002;87:2024-32.
59. Popp-Snijders C, Lips P, Netelenbos JC. Intra-individual variation in bone resorption markers in urine. Ann Clin Biochem 1996;33:347-8.
60. Gerrits MI, Vecht-Hart IM, Oldenhave A, Thijssen JH. Comparison of urinary bone resorption markers in women of 40-70 years: day-to-day and long-term variation in individual subjects. Maturitas 1998;30:247-55.
61. Kyd PA, De Vooght K, Kerkhoff F, Thomas E, Fairney A. Clinical usefulness of biochemical resorption markers in osteoporosis. Ann Clin Biochem 1999;36:483-91.
62. Green JH. Correlations between biochemical markers of bone resorption and creatinine excretion. Scand J Clin Lab Invest 2001;61:27-32.
63. Clowes JA, Hannon RA, Yap TS, Hoyle NR, Blumsohn A, Eastell R. Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone 2002;30:886-90.
64. Cummings SR, Bates D, Black DM. Clinical use of bone densitometry: scientific review. JAMA 2002;288:1889-97.
65. Scariano JK, Garry PJ, Montoya GD, Duran-Valdez E, Baumgartner RN. Diagnostic efficacy of serum cross-linked N-telopeptide (NTx) and aminoterminal procollagen extension propeptide (PINP) measurements for identifying elderly women with decreased bone mineral density. Scand J Clin Lab Invest 2002;62:237-44.
66. Chesnut CH III, Bell NH, Clark GS, Drinkwater BL, English SC, Johnson CC Jr, et al. Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med 1997;102:29-37.
67. Pedrazzoni M, Alfano FS, Girasole G, Giuliani N, Fantuzzi M, Gatti C, et al. Clinical observations with a new specific assay for bone alkaline phosphatase: a cross-sectional study in osteoporotic and pagetic subjects and a longitudinal evaluation of the response to ovariectomy, estrogens and bisphosphonates. Calcif Tissue Int 1996;59:334-8.
68. Posaci C, Altunyurt S, Islekel H, Saygili U, Altekin E, Onvural A, et al. The values of urinary NTx in postmenopausal women undergoing HRT: the role of additional alendronate therapy. Maturitas 2002;42:281-6.
69. Rubinacci A, Melzi R, Zampino M, Soldarini A, Villa I. Total and free deoxypyridinoline after acute osteoclast activity inhibition. Clin Chem 1999;45:1510-6.
70. Ross PD, Knowlton W. Rapid bone loss is associated with increased levels of biochemical markers. J Bone Miner Res 1998;13:297-302.
71. Garnero P, Vassy V, Bertholin A, Riou JP, Delmas PD. Markers of bone turnover in hyperthyroidism and the effects of treatment. J Clin Endocrinol Metab 1994;78:955-9.
72. Marshall LA, Cain DF, Dmowski WP, Chestnut CH. Urinary N-telopeptides to monitor bone resorption while on GnRH agonist therapy. Obstet Gynecol 1996;87:350-4.
73. Reeve J, Loftus J, Hesp R, Ansell BM, Wright DJ, Woo PM. Biochemical prediction of changes in spinal bone mass in juvenile chronic (or rheumatoid) arthritis treated with glucocorticoids. J Rheumatol 1993;20:1189-95.
74. Tannenbaum C, Clark J, Schwartzman K, Wallenstein S, Lapinski R, Meier D, et al. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab 2002;87:4431-7.
75. Sasaki N, Kusano E, Ando Y, Nemoto J, Iimur O, Ito C, et al. Changes in osteoprotegerin and markers of bone metabolism during glucocorticoid treatment in patients with chronic glomerulonephritis. Bone 2002;30:853-8.
76. Abildgaard N, Rixen K, Kristensen JE, Erisen EF, Nielsen JL, Heickenforff L. Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-NTx are predictive for early progression of the bone disease during standard chemotherapy. Br J Haematol 2003;120:235-42.
77. Rosen CJ, Chestnut CH, Mallinak NJS. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J Clin Endocrinol Metab 1997;82:1904-10.
78. Schneider DL, Barrett-Connor EL. Urinary N-telopeptide levels discriminate normal, osteopenic, and osteoporotic bone mineral density. Arch Intern Med 1997;157:1241-5.
79. Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C, et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study. J Bone Miner Res 1996;11:1531-8.
80. Keen RW, Nguyen T, Sobnack R, Perry LA, Thompson PW, Spector TD. Can biochemical markers predict bone loss at the hip and spine: a 4-year prospective study of 242 early postmenopausal women. Osteoporos Int 1996;6:399-406.
81. Vergnaud P, Lunt M, Scheidt-Nave C, Poor G, Gennari C, Hoszowski K, et al. Is the predictive power of previous fractures for new spine and non-spine fractures associated with biochemical evidence of altered bone remodeling? The EPOS study. Clin Chim Acta 2002;322:121-32.